10 September 2024
Oxford Nanopore Technologies plc
Oxford Nanopore seeks discovery in connection with anticipated breach of contract action
Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or "the Group"), the company delivering a new generation of nanopore-based molecular sensing technology, today announces that it has filed an ex parte application under 28 U.S.C. § 1782 in the U.S. District Court for the Northern District of California, for leave to serve subpoenas on Complete Genomics, Inc., Innomics Inc. (formerly known as BGI Americas Corp.), MGI Americas, Inc. ("MGI"), and others in support of a lawsuit that Oxford Nanopore intends to file in the courts of England and Wales.
Oxford Nanopore anticipates bringing claims against BGI Tech Solutions Co., Ltd, BGI Group, BGI, Beijing Genomics Institute at Shenzhen, MGI Holdings Co., Limited and MGI Tech Co., Ltd in England for, inter alia, claims for breach of contractual obligations, claims for breach of common law obligations of confidence, breach of duties under the Trade Secrets (enforcement etc.) Regulations 2018, and an entitlement claim to a license of certain patents.
Additionally, while not commenting on future litigation, the Group does not believe BGI's nanopore-based sequencing technology is able to be used in commercial products around the World without infringing or misappropriating the Group's substantial portfolio of proprietary rights.
-ENDS-
For further information, please contact:
Oxford Nanopore Technologies plc
Investors: ir@nanoporetech.com
Media: media@nanoporetech.com
Teneo (communications adviser to the Company)
Tom Murray, Olivia Peters
+44 (0) 20 7353 4200
OxfordNanoporeTechnologies@teneo.com
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The Group has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 125 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer. Oxford Nanopore's technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture.
For more information please visit: www.nanoporetech.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
